adesso (ADN1) Q2 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2025 earnings summary
18 Aug, 2025Executive summary
Sales grew 12% year-over-year to €709.5M in H1 2025, with Q2 revenues of €366M, driven by organic expansion and strong digitalization demand.
EBITDA increased 34% to €37.2M, with margin improving to 5.2% from 4.4% in H1 2024.
Net loss narrowed to €-6.0M from €-9.9M, and EPS improved to €-0.88 from €-1.51 year-over-year.
Employee headcount rose 7% to 10,794 FTEs, supporting business growth.
Full-year guidance reaffirmed, expecting revenue of €1.35–1.45B and EBITDA of €105–125M.
Financial highlights
Gross profit increased 10% to €598.0M; personnel costs up 10% to €493.7M.
Free cash flow was negative at -€80.8M, down 61% year-over-year, mainly due to higher net working capital and CapEx.
Net debt increased to €143.0M, mainly from acquisitions and share buybacks.
Equity ratio declined to 21.5% from 24.2% at year-end 2024.
Operating cash flow was -€44M, impacted by higher trade receivables and contract assets.
Outlook and guidance
On track to achieve full-year revenue guidance of €1.35–1.45B and EBITDA of €105–125M, with higher earnings expected in H2 due to more working days and increased IT spending.
Margin target set above 7.6%, with expectations to surpass last year’s margin.
Anticipates increased IT spending in the public sector and further license sales in H2.
Latest events from adesso
- Sales up 11% with margin pressure; H2 2025 expected to drive earnings recovery.ADN1
Q1 2025 TU3 Feb 2026 - Sales up 16% to €631.1m, but negative EPS and lower EBITDA guidance due to margin pressure.ADN1
H1 20241 Feb 2026 - Record sales and profitability in Q3 2024, with strong outlook and share buyback underway.ADN1
Q3 2024 TU14 Jan 2026 - Sales, EBITDA, and EPS surged, with robust sector growth and guidance at the upper end.ADN1
Q3 202515 Nov 2025 - 14% organic growth and margin gains set stage for further expansion in 2025.ADN1
H2 20245 Jun 2025